Results from a published multicenter study
The annual general meeting, held 23rd of May 2017, approved the re-election of Jerker Swanstein, Max Pihlqvist, Hans Örström and Peter Brätuigam. During the statutory meeting held 24th of May 2017 Hans Örström was selected as new Chariman of the Board.
The study published in Scandinavian Journal of Urology (https://www.ncbi.nlm.nih.gov/pubmed/28422550) was conducted at four Swedish hospitals; Uppsala University Hospital, Danderyds hospital, Enköping Hospital and Umeå University Hospital. Principal investigators was Assoc. Prof Amir Sherif, Umeå University.
Vid årsskiftet slutar Hans Örström som VD på IDL Biotech AB. Charlotte Berg är utsedd som efterträdare.
Artikel publicerad på innovationmotcancer.se